Dear Editor,

The postulated importance of mechanical power is that it provides a unifying concept combining the interaction of all the individual components of mechanical ventilation with the patient. Derived from the equation of motion, mechanical power calculates the energy delivered over time to the respiratory system by the ventilator \[[@CR1]\]. Physiologically, mechanical power incorporates tidal volume, pressure, and additional parameters not included in driving pressure \[[@CR2]\]. Previous studies demonstrated an association of power with mortality \[[@CR3]--[@CR5]\], but were primarily in non-ARDS populations \[[@CR4]\], lacked consistent findings within all ARDS severities \[[@CR3]\], or were unadjusted and descriptive of a single mechanical power threshold \[[@CR5]\]. None assessed whether the association of mechanical power and mortality was independent from driving pressure.

To assess the relative strength of association of mechanical power and driving pressure (Δ*P*) with mortality, we pooled patients from three randomized controlled trials of ARDS. Methods are detailed in the Online data supplement, but briefly, we reconstructed the adjusted Cox proportional hazards model from the Amato et al. driving pressure \[[@CR2]\] study (Table E1) and examined the relationship between Δ*P* with mortality, mechanical power with mortality, and, after checking for correlation and multicollinearity, we combined both Δ*P* and mechanical power in the same model. We also visually examined the relationship of Δ*P* and mechanical power with mortality. We analyzed patients not making respiratory efforts, and did a sensitivity analysis on patients making respiratory efforts.

We found that among 1294 patients without respiratory efforts (Figure E1, Table E2), Δ*P* was significantly associated, in adjusted analysis, with 60-day hospital mortality (hazard ratio \[HR\] 1.44 \[95% CI 1.28, 1.62; *p* \< 0.001\]) (Table E2). Replacing Δ*P* with mechanical power, the HR was 1.39 (95% CI 1.28, 1.52; *p* \< 0.001). Including *both* Δ*P* and mechanical power in the same model, each retained an independent significant relationship with mortality (Δ*P*: HR 1.2 \[95% CI 1.03, 1.4; *p* = 0.018\]; mechanical power: HR 1.26 \[95% CI 1.11, 1.43; *p* \< 0.001\]) (Table E3). Sensitivity analyses among patients making respiratory efforts were unchanged (Table E6). Increasing quintiles of mechanical power, stratified on comparable levels of Δ*P*, were significantly associated with mortality (HR 1.19 \[95% CI 1.1, 1.3; *p* \< 0.001\]) (Fig. [1](#Fig1){ref-type="fig"}a); the converse was also true (HR 1.12 \[95% CI 1.03, 1.22; *p* = 0.007\]) (Fig. [1](#Fig1){ref-type="fig"}b).Fig. 1Hazard ratio of in hospital death across relevant subsamples after multivariate adjustment. Multivariate adjusted hazard ratio of 60-day in-hospital death across patient strata. Strata in **a** (upper) have comparable values of driving pressure, but increasing values of mechanical power across strata. HR for each stratum is presented below. **b** Has comparable values of mechanical power, but increasing values of driving pressure across strata. Y1 axis is airway pressure; Y2 axis is mechanical power normalized to compliance. X axis reports cohort sample sizes

That mechanical power retains a significant relationship with mortality, despite adjusting for driving pressure, may be because mechanical power relies on other components than driving pressure itself. Clinically modifiable parameters such as flow and respiratory rate could also have an effect on mortality in ARDS patients. Like Δ*P*, mechanical power is normalized to individual compliance, but additionally includes respiratory rate and flow to quantify and include repetitive and dynamic forces. Mechanical power thus captures an applied energy in a way that driving pressure does not. It provides additional risk estimation beyond driving pressure alone. Our results suggest a need for prospective interventional trials to examine the clinical effect of a mechanical power reduction ventilation strategy compared to either a tidal volume or to a driving pressure managed strategy.
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